Jump to content



Recommended Posts

In reply to: wolverine on Friday 31/10/08 12:03pm

Hi Wolv


Thank you for your post.


What you say is correct. Theretically, you only lose the number of shares but the value stays the same. Theoretically!


My experience is that in most cases the share price drops back to about the same level it was. In other words it results in massive destruction of value.

I know of only two cases where the share has appreciated to the equivelant value. Packer consolidating Bond Media and Pacific Dunlop. But even these are failures. Pacific Dulop was trading at $2.20 pre its 1 for 5 consolidation, and paying a $0.20 dividend. Ansel is now at $12 and paying a $0.26 dividend. And the funny thing is, I have had one of the best and respected poster on SS calling me a fool to suggest that its been a failure. He actually thinks the dividend return is the same!


I just don't understand how anybody could think that at these levels VCR is a bargain. It may well be and its your money but I would suggest that you try and answer Lei question before you give these fools your hard earned cash. We still have a long way to go before approval and then there is no guarantee that they will be commercially successful in the USA. Itis still a gamble in my view.


I would have thought that in the present market there are plenty of bargains which are not a gamble.














Link to comment
Share on other sites

  • Replies 13.3k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images




VENTRACOR: A HEART BEAT AWAY November 1st 2008 01:37
Biotech Daily

Monday October 27, 2008

Daily news on ASX-listed biotechnology companies

MARC SINATRAÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢S BIOGUIDE: VENTRACOR

Overview: Back in mid-2003, Ventracor found blue sky and its share price rocketed to more than three dollars.

Then in a strange move, two US-based ventricular assist device (VAD) companies, Sunshine Heart and Heartware, listed on the ASX.

The signal to me was clear, Australia was significantly over-valuing VAD companies.

While avoiding these companies has proved prudent, VentracorÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s share price has fallen as low as 8.0 cents.

Is it finally a good buy?

Financials: Market cap: $24 million; cash: $18 million; last half burn: $10 million.

Directors: Non-executive chairman, John Ward; CEO, Peter Crosby; non-executive directors, Ross Harricks; Elizabeth Nosworthy; Jeffrey Goodman; William E Curran.

VentracorÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s board has a solid and balanced mix of individuals focusing on medical devices. In particular, CEO Peter Crosby has an exceptional knowledge of the industry.

Products on market or in development:
Ventrassist is a VAD designed to provide circulatory support for patients with severe or class IV systolic heart failure. It consists of an internal pump attached to the left ventricle and aorta via cannulae. An external controller and battery pack attaches to the pump via a percutaneous lead.

Ventrassist gained ConformitÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚©e EuropÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚©enne (CE) Mark approval in December 2006. It is in two US registration directed trials; one a bridge-to-heart transplant (BTT) and the other a long-term destination therapy (DT) for transplant ineligible patients. Ventracor expects US Food and Drug Administration approval for the BTT indication in mid-late 2010 and for the DT indication in mid 2013.

In 2010, Ventracor expects to modify the Ventrassist system such that the controller and battery pack are also implanted.

Last year, Ventrassist generated revenue of $17.3 million via the sale of 189 devices. VentrassistÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s US Medicare classification means Ventracor is reimbursed for the device despite its investigational status.

Significant Product Markets: Five to seven million Americans have heart failure, approximately half with systolic heart failure. Five to 15 percent or 150,000 to 450,000 patients have symptoms of class IV heart failure.

Five thousand heart transplants were performed in 2007, 1,692 in the US. About 2,700 Americans are awaiting a transplant at any one time. The BTT market is about 1000 devices a year and Millennium research estimated the 2007 BTT market to be worth approximately $US75 million.

Six VADs have CE Marking, while only two have US FDA approval for BTT. A further three devices are in the early stages of, or close to, commencing US BTT trials. Two of these are third generation devices. Many more are in development.

About 25,000 - 75,000 US patients with class IV heart failure are suitable for destination therapy. A recent review indicated VAD sales were likely to be at the lower end of this range.

All CE Marked VADs can be used in Europe for DT. No VADs are approved for DT in the US and only two, Ventrassist and ThoratecÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s Heartmate II, are in US trials for the indication.

The idea of using VADs as a destination therapy is not new, but the reliability of available devices has been an issue. To increase reliability, newer devices have been greatly simplified. It is thought that when VADs can perform well for two years, DT will be viable.

Opinion: When analyzing Ventracor, two major questions arise; how big will the DT market be and how big a slice of it can they grab?

I favor market size estimates at the lower end of the range above. The reasons for this are primarily the invasiveness and the high cost of the procedure. Nonetheless, the low end still equates to a US market size of $US2.5 billion alone.

Ventracor has, and should garner further, significant revenues from Ventrassist. The company is two years ahead of its third generation rivals and is likely to be the second entrant into the US BTT market, behind ThoratecÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s second generation Heartmate II.

Other than Thoratec, competitors may find it hard to recruit patients given Ventracor has tied up many US trial sites and the small number of patients suitable for BTT trials. BTT patients also have the option of using a good approved device rather than having to put up with the demands of a clinical trial to get one. The same situation may arise in the DT space as well.

One current disadvantage of Ventrassist is that, unlike VADs such as Jarvik Heart's Jarvik 2000 and HeartwareÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s HVAD, the pump is placed in the abdomen, such that the cannulae must go though the diaphragm making the surgery more difficult. However, this disadvantage should vanish in the near future when fully implantable systems come into play and are likely to only be viable in the abdomen.

VentracorÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s only real problem is it needs cash to ensure its strong position. When blue sky vanishes, as it does, share prices are left worse off than if it had never been found and it is happening to Ventracor in the midst of terrible market conditions.

I have calculated a discount cash flow analysis valuation for Ventracor of 38 cents a share, but this is contingent on a successful capital raising.

Ventracor fell 1.5 cents or 15.46 percent to 8.2 cents with 2.5 million shares traded.

Marc SinatraÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s Bioguide
Link to comment
Share on other sites

In reply to: boo on Sunday 02/11/08 08:13pm

Thanks boo


That's a pretty good summary of the situation. Ventracor has a good product, but getting it successfully to market has been fraught. I still hold a small parcel and live in hope. I think I held on because I so want an Aussie company to do well in this high-tech area. Very poor investment strategy though !!



J http://www.sharescene.com/html/emoticons/smile.gif

Link to comment
Share on other sites

In reply to: boo on Sunday 02/11/08 08:13pm

Thanks boo


The article answers a question I had about placing of the pump in the abdomen. Finally, it makes sense.


"One current disadvantage of Ventrassist is that, unlike VADs such as Jarvik Heart's Jarvik 2000 and HeartwareÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s HVAD, the pump is placed in the abdomen, such that the cannulae must go though the diaphragm making the surgery more difficult. However, this disadvantage should vanish in the near future when fully implantable systems come into play and are likely to only be viable in the abdomen."


Link to comment
Share on other sites

In reply to: boo on Wednesday 29/10/08 12:34pm



Item 3. Remuneration Report, in the Explanatory Memorandum for the AGM, notes that a shareholder vote is advisory only [their emphasis]. In other words, vote what you like but we don't have to listen or accept it. We [the Directors] will determine our share of the trough and take it anyway.


Unable to raise cash from institutions or "sophisticated" investors, the company decides to cut back on expenditure, with no undertaking by Directors to take a cut in fees, and then throws itself at the mercy of, presumably, "unsophisticated" investors/shareholders with the sop that you can only apply for up to $5,000 worth of shares. My take on that is arrogance, or that is all they are prepared to put up individually to show they are supporting the company.


Also, all of a sudden, they only need $10m when a couple of weeks ago they needed $20m, because they can cut back on everything but the trials. Putting the fully implantable R&D on hold, which is arguably the development that would put them in the forefront when introduced, is a poor strategy in my opinion despite whatever extra cash raising may have been involved.


Pardon me borrowing your name, but BOO to the whole lot of them.

Link to comment
Share on other sites

In reply to: Clocker on Monday 03/11/08 08:46am

I have also noticed that, the 15% to sophis. Inv. (if they can find them), will be after the retail raising = more dilution.


In June 2009, there will be more capital raising to fund the commercialisation.


This gravy train just doesn't seem to stop does it??


I posted this before, they would not be going to retail investors (eg. posters on this site), if they can secure the funds elsewhere.


IMO, anyone who gives them more money (SPP), has more money than than they know what to do with it, and even then, there are far better investments than this company.

Link to comment
Share on other sites

In reply to: Clocker on Monday 03/11/08 08:46am

April 2006


ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“The Company remains on track to achieve key milestones and revenue expansion as a result of sales of the VentrAssist during its clinical trial in the United States.


The placement and rights issue give the Company cash reserves of approximately $60 million.


ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Ventracor will prudently use these funds to contribute to the funding of the clinical trials, regulatory approval and commercialisation processes of the VentrAssist along with the advancement of next generations of the VentrAssist,ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ Mr Massey said.



Link to comment
Share on other sites




Boards can't ignore investor vote on exec pay
Stuart Wilson | November 04, 2008

"Companies need to tread carefully in their response to these substantial votes. The non-binding vote was implemented in order to test its effectiveness before any further reforms were considered. Since then a completely binding vote has been introduced in countries such as France, Sweden, Norway, Spain and The Netherlands. If Australian companies do not heed the wishes of their shareholders, there is a risk that we could easily find ourselves added to this list."


Link to comment
Share on other sites

Little tidbit to get people interested in the SPP today!!!!

European Progress

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ 100th European patient

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ New cannula family receives CE Mark approval

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ 17 year old patient experiences heart recovery and explant

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢ 10 year old patient implanted

Sydney AUSTRALIA 5 November 2008: Ventracor Limited (ASX:VCR) reported today

significant progress in the European commercialisation of the VentrAssistÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® Left

Ventricular Assist Device (LVAD).

The 100th patient to receive a VentrAssist LVAD in Europe was implanted on 29th

October 2008 at the Klinik fÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¼r Thorax- und Kardiovaskularchirurgie, Ruhr-UniversitÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¤t

Bochum ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ Bad Oeynhausen in Germany by Univ-Prof. Dr. Dr. h. c. Reiner KÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¶rfer. The

patient, a 47-year old man with an idiopathic dilated Cardiomyopathy, continues to make

an uneventful recovery.

Ventracor Chief Executive Officer, Mr. Peter Crosby said: ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Bad Oyenhausen is one of the

most prestigious hospitals implanting LVADs in the world, and we are honoured that they

have chosen Ventracor as a partner.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

Ventracor also announced CE Mark approval of a new family of in-flow cannulae ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ the

tube that connects the heart to the pump. The first of the new cannula family is pre-bent,

more flexible, and has a textured intra-ventricular section. The new cannula is designed

to give more options to surgeons when implanting the VentrAssist LVAD, and is in

recognition of the principle that one size does not fit all. The Company intends to seek

FDA approval to introduce the new cannula into US clinical trials as soon as possible.

In an exciting development, Ventracor reported the recovery of the heart of 17 year old

girl after 413 days of support with the VentrAssist LVAD implanted after viral myocarditis.

The surgery was performed by Dr. Arnt Fiane from the Department of Cardiac Surgery

under Professor Odd Geiran at the Rijkshopitalet in Oslo, Norway. Dr. Fiane said: ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“This

case shows that patients can go on to recover after long term support by the VentrAssist

LVAD, and we hope to see more as our experience grows.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

Also at the Rikshospitalet in Oslo further significant achievements were made by a team

jointly led by Dr. Harald Lindberg (Paediatric Cardiac Surgeon) and Dr. Arnt Fiane to

implant a VentrAssist LVAD into the smallest patient to date ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ a ten-year old boy

weighing 34kg. He continues to make a good recovery and has returned to school just

three weeks after the implant procedure

In Germany, Prof. Dr. med. Hans H. Scheld led a team at the UniversitÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¤tsklinikum

MÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¼nster, Klinik und Poliklinik fÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¼r Thorax-, Herz- und GefÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¤ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Â¦Ãƒƒâہ¡ÃƒÆ’‚¸chirurgie, in their first implant

of the VentrAssist device. This group has a long experience with mechanical circulatory

support, and Professor Scheld said ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“We are pleased to have moved on to using thirdgeneration devices and are impressed by the VentrAssist system so far. Our first patient continues to recover even though he was very ill at the time of implant. We look forward to continuing our partnership with Ventracor.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ

The Company also reported that there were 27 implants of the VentrAssist LVAD

worldwide during the month of October. With over 370 patients implanted with the

VentrAssist LVAD to date, and 122 patients implanted in the US Bridge To Transplant

(BTT) clinical trial, there is more clinical experience with the VentrAssist LVAD than with

all other third generation centrifugal LVADs combined


Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...